Glucagen Hypokit

Glucagen Hypokit is an injectable solution that contains the active ingredient glucagon. It is supplied in a dosage form designed for intramuscular, intravenous, or subcutaneous administration. Marketed in the European Union as a prescription‑only product, Glucagen Hypokit provides a rapid means to increase blood glucose levels in patients experiencing severe hypoglycemia. The preparation does not contain a specified strength on the label or dosage specification.

Glucagen Hypokit is indicated for the emergency treatment of severe hypoglycemia when rapid glucose elevation is required.

- Adults and children with insulin‑induced hypoglycemia who cannot safely consume oral carbohydrates. - Situations where blood glucose is < 50 mg/dL (2.8 mmol/L) and the patient is symptomatic. - Use during diabetic emergencies in hospital, outpatient, or home settings when immediate correction is needed. - Administration by trained healthcare professionals or caregivers following a hypoglycemia protocol. - As a rescue medication for patients on insulin pump therapy experiencing pump failure.

The safety profile of Glucagen Hypokit reflects the pharmacologic actions of glucagon and the route of injection.

Common: - Nausea or vomiting, typically occurring shortly after injection. - Flushing, warmth, or mild erythema at the injection site. - Headache that resolves within a few hours. - Transient increase in blood pressure or heart rate.

Serious: - Severe allergic reaction (anaphylaxis) presenting with difficulty breathing, swelling, or hives. - Hypersensitivity skin reactions such as rash, itching, or angio‑edema. - Cardiac arrhythmia or chest pain in patients with pre‑existing heart conditions.

When using Glucagen Hypokit, clinicians should observe several precautions to ensure safe and effective treatment.

- Verify hypoglycemia with a blood glucose measurement before administration, unless the patient is unconscious. - Use only the prescribed dosage and avoid repeat dosing without medical supervision. - Monitor the patient’s vital signs and glucose level after injection. - Exercise caution in patients with pheochromocytoma, adrenal insufficiency, or known glucagon hypersensitivity. - Avoid use in individuals with severe cardiovascular disease unless benefits outweigh risks. - Store the kit at controlled room temperature and protect from light. - Discard any solution that appears discolored or contains particles.

Glucagen Hypokit may interact with certain medications or clinical conditions, influencing its efficacy or safety.

Avoid: - Beta‑blockers, which may mask typical glucagon‑induced tachycardia and affect glucose response. - Insulin secretagogues (e.g., sulfonylureas) that can precipitate recurrent hypoglycemia after glucagon administration. - Monoamine oxidase inhibitors (MAOIs) that may potentiate cardiovascular effects.

Use with caution: - Anticholinergic agents, as they may blunt the glycogenolytic response. - Calcium channel blockers, which could affect hemodynamic stability. - Patients receiving catecholamines or other vasoactive drugs; monitor blood pressure closely.